Corona Biomask

Grant number: LMVFA20665

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2022
  • Known Financial Commitments (USD)

    $25,660,518.82
  • Funder

    Estonian Research Council
  • Principal Investigator

    Kogermann Karin
  • Research Location

    Estonia
  • Lead Research Institution

    University of Tartu
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The aim of the project is to develop a colostrum polyclonal antibody nasal spray preparation which is able to effectively inactivate the SARS-CoV-2 virus particles in nasal mucosa. Active molecules in the preparation are hyperimmune bovine colostrum derived SARS-CoV-2 S protein-specific enriched immunoglobulins. Gestating cows will be immunized three times with SARS-CoV-2 S protein. After the calves are born, the colostrum will be collected in different fractions followed by lipid removal and casein coagulation with chymosin. The resulting whey is further centrifuged, fraction precipitated, heat-treated and sterile-filtered, resulting in a bovine colostrum derived immunoglobulin solution that will be further formulated into a nasal spray. The virus neutralizing activity of the antibodies will be separately tested and the antibody preparation will be administered into the nasal cavity in order to develop an environment which will inactivate the virus in the nasal mucosa.